

1           **Appraising the causal association between gut microbiota and**  
2           **immune-related adverse events: perspectives from a bi-directional**  
3           **Mendelian randomization study**

4  
5           **Baike Liu<sup>1,2,5</sup>, Zheran Liu<sup>3,5</sup>, Tianxiang Jiang<sup>1,2,5</sup>, Xiangshuai Gu<sup>4</sup>, Xiaonan Yin<sup>1,2</sup>,**  
6           **Zhaolun Cai<sup>1,2</sup>, Xiaoqiao Zou<sup>1,2</sup>, Lei Dai<sup>4\*</sup>, Bo Zhang<sup>1,2\*</sup>**

7  
8           <sup>1</sup> Department of General Surgery, West China Hospital, Sichuan University, Chengdu,  
9           Sichuan, 610041, the People's Republic of China.

10          <sup>2</sup> Gastric Cancer Center, West China Hospital, Sichuan University. Chengdu, Sichuan,  
11          610041, the People's Republic of China.

12          <sup>3</sup> Department of Biotherapy and National Clinical Research Center for Geriatrics,  
13          Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, the  
14          People's Republic of China.

15          <sup>4</sup> State Key Laboratory of Biotherapy and Cancer Center, West China Hospital,  
16          Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu,  
17          Sichuan, 610041, the People's Republic of China.

18          <sup>5</sup> These authors contributed equally: Baike Liu, Tianxiang Jiang, Zheran Liu.

19          \*e-mail: [zhangbo\\_scu@scu.edu.cn](mailto:zhangbo_scu@scu.edu.cn), [daileisklb2012@163.com](mailto:daileisklb2012@163.com)

20  
21  
22          Running title: Causal associations between gut microbiota and irAEs

33 **Abstract:**

34 **Background:** Emerging evidence suggested that the gut microbiota associated with  
35 the development of immune-related adverse effects (irAEs) among cancer patients  
36 receiving immune checkpoint inhibitors (ICIs), but their roles remain largely  
37 unknown, and the causal associations are yet to be clarified.

38 **Methods:** Bi-directional two-sample Mendelian randomization (MR) approach was  
39 employed to examine the potential causal relationship between the gut microbiome  
40 and irAEs (high-grade irAEs and all-grade irAEs). Instrumental variables (IVs) for  
41 gut microbiota were retrieved from the MiBioGen consortium (18,340 participants).  
42 GWAS summary data for instrument-outcome associations were gathered from an  
43 ICIs-treated cohort with 1,751 cancer patients. Inverse variance weighted (IVW), MR  
44 PRESSO, maximum likelihood (ML), weighted median, weighted mode, and  
45 cML-MA-BIC were used in the MR analysis. Reverse MR analysis was performed on  
46 the identified bacteria that were causally associated with irAEs.

47 **Results:** Fourteen gut bacterial taxa identified by IVW and MR PRESSO were  
48 causally associated with irAEs, among which *Lachnospiraceae* was shown to increase  
49 the risk of both high-grade and all-grade irAEs. *Akkermansia*, *Verrucomicrobiaceae*,  
50 and *Anaerostipes* were found to exert protective roles in high-grade irAEs.  
51 Nevertheless, *Ruminiclostridium6*, *Coprococcus3*, *Collinsella*, and *Eubacterium*  
52 (*fissicatena* group) predispose to the development of high-grade irAEs. For all-grade  
53 irAEs, *RuminococcaceaeUCG004*, and *DefluviitaleaceaeUCG011* were shown to  
54 have protective effects. While on the contrary, *Porphyromonadaceae*, *Roseburia*,  
55 *Eubacterium (brachy* group), and *Peptococcus* were associated with an elevated risk  
56 of all-grade irAEs.

57 **Conclusion:** Our MR analysis found that *Lachnospiraceae* and *Akkermansia* et al.  
58 were causally associated with the development of irAEs, which warrants further  
59 investigation.

60

61

62 **Key words:** Gut microbiota, Immune-related adverse effects, irAEs, *Lachnospiraceae*,  
63 *Akkermansia*, Mendelian randomization study

64

65

66

67

68

69

## 70 **1. Introduction**

71 Applications of immune checkpoint inhibitors (ICIs), especially those targeting  
72 CTLA-4 and PD-1/PD-L1, have revolutionized the treatment of various aggressive  
73 cancers (1). By blocking inhibitory signaling pathways and reinvigorating the natural  
74 anti-tumor immune response, these inhibitors have significantly prolonged the lives of  
75 numerous cancer patients (2–5). However, due to the inhibition of the systemic brake  
76 of immune activation, ICIs can cause off-target effects resulting in immune-mediated  
77 impairment of organs and non-malignant tissues. This newly emerging registry of  
78 iatrogenic effects, known as immune-related adverse effects (irAEs), usually resemble  
79 autoimmune disorders, such as colitis, dermatitis, and thyroiditis (6). Although the  
80 majority of irAEs manifest in a mild manner, still, up to 55% of patients develop  
81 serious irAEs in combined therapy (anti-CTLA-4 and anti-PD-1) (7). Notably, serious  
82 irAEs pose significant risks to patients' well-being and may result in morbidity and  
83 mortality, not only due to the adverse event itself but also due to the need to suspend  
84 or terminate ICIs therapy and the potential impairment of the ICIs-induced immune  
85 response while using immunosuppressants (e.g. corticosteroids) (8–10). Therefore,  
86 effective management of irAEs is critical to optimize the safety and efficacy of ICIs  
87 therapy.

88 The precise mechanisms underlying irAEs are not fully understood, but  
89 emerging evidence indicates that the gut microbiota, a complex and dynamic system  
90 of microorganisms colonizing the intestinal tract, may play a crucial role in the  
91 regulation of irAEs. Simpson et al. found a reduced alpha-diversity of intestinal  
92 microbiota in patients who developed severe irAEs (11). Furthermore, antibiotics  
93 commonly prescribed prophylactically to hospitalized patients have been shown to  
94 increase the risk of ICIs therapy-related irAEs that are not limited to the  
95 gastrointestinal tract (12–14). The gut microbiota is closely interacted with the host  
96 immune system and has been implicated in the regulation of various autoimmune and  
97 inflammatory disorders (15,16). However, consensus on the core microbial drivers or  
98 protective microbes of irAEs is still lacking, due to inconsistent findings reported in  
99 previous studies (11,17–19). The discrepancies among previous studies may be  
100 attributed to limited sample sizes and susceptibility to confounding factors such as age,  
101 diet, and medication usage in observational designs (11,20).

102 Mendelian randomization (MR), initially described by Katan in 1986 (21), is a  
103 novel method for inferring causal associations between modifiable risk factors and  
104 health outcomes using genetic variations as instrumental variables (IVs) (22). MR  
105 effectively addresses the limitations of confounding and measurement errors that  
106 often exist in observational studies, as the direction of causation is from the genetic  
107 polymorphism to the trait of interest, not vice versa (23). Therefore, we aim to utilize

108 MR, an increasingly popular method in drug discovery and epidemiology (24,25), to  
109 investigate the potential association between the gut microbiota and irAEs, providing  
110 further evidence for the management of irAEs through manipulating the human gut  
111 microbiota.

112

## 113 **2. Methods**

### 114 **Study design and data source**

115 An overview of the study design was illustrated in **Figure 1**. In general, we  
116 performed a bi-directional two-sample Mendelian randomization, a genetic  
117 instrumental variable analysis that utilizes single nucleotide polymorphisms (SNPs)  
118 from summary-level data as genetic instruments for the risk factor under investigation.  
119 To ensure the validity of the MR results, three assumptions needed to be satisfied, as  
120 illustrated in **Figure S1** (22): (1) the genetic variants should demonstrate a strong  
121 association with the exposure (relevance assumption); (2) the genetic variants should  
122 not be associated with any confounders that could affect the relationship between the  
123 exposure and outcome (independence assumption); and (3) the variants should not  
124 have an independent effect on the outcome aside from their impact through the  
125 exposure (exclusion restriction assumption). This study is based on publicly available  
126 GWAS summary statistics and ethical approvals were acquired in the original study.

127

128 **Gut microbiota:** Genetic variations associated with the composition of gut  
129 microbiota were derived from the most comprehensive genome-wide meta-analysis  
130 conducted to date by the MiBioGen consortium (26). This study included a total of  
131 18,340 individuals from 24 cohorts worldwide, mainly of European descent (n =  
132 13,266). Fecal DNA was extracted, and targeted sequencing of variable regions in the  
133 bacterial 16S rRNA gene (V4, V3-V4, and V1-V2 regions) was performed to profile  
134 the gut bacterial composition. To account for sequencing depth differences across  
135 cohorts, all cohorts were rarefied to 10,000 reads per sample. Taxonomic  
136 classification was performed using direct taxonomic binning method (26). Following  
137 quality control, imputation, and post-imputation filtering procedures, gut bacterial  
138 taxa observed in over 10% of samples were included in the microbiota quantitative  
139 trait loci (mbQTL) mapping (26). This allowed us to identify host genetic variants  
140 associated with the relative abundance of bacterial taxa. Further details on microbial  
141 data processing can be found in the original study. Genus-level and family-level taxa  
142 were included in our analysis, resulting in a total of 131 genus-level and 35  
143 family-level taxa.

144

145 **irAEs:** Summary-level data of irAEs was obtained from a recent GWAS

146 conducted in the Dana-Farber Cancer Institute (DFCI) cohort (27). The study included  
147 1,751 cancer patients of European ancestry who underwent ICIs treatments between  
148 2013 and 2020. The majority of patients (approximately 90%) received PD-1/PD-L1  
149 inhibitors, while the remaining 10% received combined immunotherapy (CTLA4 and  
150 PD-1/PD-L1 inhibitors). Among the 1,751 cancer patients, 259 cases that experienced  
151 high-grade irAEs (grade 3 to 5 events) were manually curated according to the  
152 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events  
153 v.5 guidelines. Additionally, algorithm-based autoimmune-like electronic health  
154 records were used to identify 339 patients who experienced any grade irAEs (referred  
155 to as all-grade irAEs). Most of these cases were grade 2 or higher events (27). The  
156 tumor tissue of these patients was sequenced using the targeted OncoPanel  
157 sequencing platform. After quality control steps, germline SNPs were imputed by  
158 utilizing ultra-low-coverage off-target reads. Then, the GWAS was conducted in the  
159 DFCI cohort to investigate the association of all variants with the time from the start  
160 of ICIs treatment to the occurrence of the two phenotypes of irAEs. For more detailed  
161 information, please refer to the original publication (27).

162

### 163 **Selection of instrumental variables**

164 Several steps were followed in the selection of IVs. Firstly, for the gut  
165 microbiome, we selected SNPs associated with bacterial taxa with a p-value less than  
166  $1 \times 10^{-5}$  for further analysis (28,29). Secondly, potential SNPs were clumped for  
167 independence in the TwoSampleMR package in R software. We used the European  
168 1000 Genomes Project Phase 3 reference panel and set the linkage-disequilibrium  
169 threshold ( $r^2$ ) at 0.001 within a 10 Mb window size. Thirdly, we extracted SNPs from  
170 the outcome statistics and performed a harmonization procedure. SNPs that were not  
171 available in the outcome GWAS data were replaced with proxy SNPs ( $r^2 > 0.8$ ), and  
172 palindromic SNPs were removed for further MR analysis. Furthermore, F statistics of  
173 selected IVs, which indicate instrument strength, was calculated as  $[\text{Beta}/\text{SE}]^2$ .  
174 Typically, F statistics  $> 10$  suggest enough IVs strength to avoid weak instrument bias  
175 (30). Finally, All SNPs with positive results were re-examined using PhenoScanner  
176 package (version 1.0) in R software to investigate the presence of potential  
177 confounders. Bacterial taxa with less than 3 valid SNPs and unknown origin were  
178 excluded from the analysis to mitigate potential bias. Consequently, we included a  
179 total of 104 genus-level and 28 family-level bacterial taxa ( $n = 132$ ) for further MR  
180 analysis.

181

182 **Statistical analysis**

183 In this study, we employed several MR analysis methods to explore the potential  
184 causal relationship between gut microbiota and irAEs. The methods used included  
185 IVW, MR PRESSO, ML, weighted median, weighted mode, and a constrained  
186 maximum likelihood and model averaging based method (cML-MA-BIC). IVW and  
187 MR PRESSO were used in the primary analysis. In general, IVW provides maximum  
188 statistical power when all instruments are valid (31), while MR PRESSO identifies  
189 and removes genetic variants that deviate significantly from the variant-specific  
190 causal estimates of other variants, thereby increasing statistical power and addressing  
191 potential outliers (32). The ML method is similar to the IVW approach which assumes  
192 the absence of both heterogeneity and horizontal pleiotropy. If these assumptions hold  
193 true, the ML method yields unbiased results with smaller standard errors compared to  
194 the IVW approach (33). Considering the potential existence of IV pleiotropy, we also  
195 performed pleiotropy-robust methods including weighted median, weighted mode,  
196 and cML-MA-BIC in the sensitivity analysis. These methods relax the instrumental  
197 variable assumptions. Weighted median were introduced when the exclusion  
198 restriction assumption was violated (uncorrelated pleiotropy), which typically assume  
199 fewer than 50% of genetic variants are invalid (34). The weighted-mode method  
200 clusters genetic variants based on their similarity in causal effect and estimates the  
201 overall causal effect based on the cluster with the most number of IVs (35). The  
202 cML-MA-BIC method is a novel approach developed for MR analysis, specifically  
203 addressing the issue of invalid IVs exhibiting both uncorrelated and correlated  
204 pleiotropy (violation of the independence assumption) (36). By being robust to such  
205 violations, cML-MA-BIC improves the accuracy of MR analysis, reduces Type I error,  
206 and increases statistical power (36).

207 Next, heterogeneity and directional pleiotropy were assessed using Cochran's Q  
208 statistics and MR Egger intercept. Leave-one-out (LOO) analysis was conducted to  
209 identify possible reliance on a specific variant, which involved excluding one SNP at  
210 a time for all valid SNPs in the IVW analysis. Additionally, reverse MR analysis  
211 between irAEs and the identified significant gut bacterial taxa was performed. We  
212 considered a Bonferroni-corrected p-value of  $3.89 \times 10^{-4}$  (0.05/132) as the  
213 significance threshold for gut microbiota. Two-tailed p-values < 0.05 was considered  
214 suggestive of significance. All analyses were conducted using R packages  
215 "TwoSampleMR" (version 0.5.6), "MRPRESSO" (version 1.0), and "MRcML"  
216 (version 0.0.0.9) in R software (version 4.2.2).

217

### 218 3. Results

#### 219 3.1 Genetic instruments and primary MR analysis

220 A total of 870 single nucleotide polymorphisms (SNPs) were selected as  
221 instrumental variables (IVs) for the 132 gut bacterial taxa (**Table S1**). The F statistics  
222 for each SNP ranged from 16.91 to 36.57, with a median value of 21.66. Using the  
223 IVW and MR-PRESSO methods, eight gut bacterial taxa associated with high-grade  
224 irAEs were identified with p-values < 0.05. These taxa include *Lachnospiraceae*,  
225 *Verrucomicrobiaceae*, *Ruminiclostridium6*, *Coproccoccus3*, *Anaerostipes*,  
226 *Akkermansia*, *Collinsella*, and *Eubacterium (fissicatena group)*. For all-grade irAEs,  
227 seven gut bacterial taxa, including *Lachnospiraceae*, *Porphyromonadaceae*,  
228 *Roseburia*, *RuminococcaceaeUCG004*, *DefluviitaleaceaeUCG011*, *Eubacterium*  
229 (*brachy group*), and *Peptococcus*, were identified. Given previous studies suggest that  
230 pre-existing autoimmune conditions such as inflammatory bowel disease, psoriasis,  
231 and rheumatoid arthritis may predispose individuals to irAEs susceptibility (37,38).  
232 We further examined the SNPs associated with the significant bacterial taxa using  
233 PhenoScanner. Only one SNP (rs11597285) for the *Collinsella* genus was found to be  
234 associated with allergic disease (e.g. allergic rhinitis and eczema) (refer to **Table S9**).  
235 However, the results of *Collinsella* remained uninfluenced after removing rs11597285  
236 in the LOO analysis (described below). The complete results of the primary MR  
237 analysis can be found in **Table S2** and **Table S3**.

238

#### 239 3.2 Main MR results and sensitivity analysis for high-grade irAEs

240 As shown in **Figure 2**, the IVW estimate suggested the abundance of  
241 *Lachnospiraceae* family was associated with a shortened time to high-grade irAEs  
242 (Beta = -1.22, 95% CI: -1.99 to -0.44,  $p = 2.17 \times 10^{-3}$ ), indicating *Lachnospiraceae*  
243 serves as a risk factor for the development of high-grade irAEs. The deleterious effect  
244 remained significant in pleiotropy-robust cML-MA-BIC estimation (Beta = -1.24, 95%  
245 CI: -2.45 to -0.02,  $p = 4.62 \times 10^{-2}$ ). Surprisingly, *Ruminiclostridium6* genus was  
246 significantly associated with an increased risk of high-grade irAEs in all MR  
247 approaches, including IVW (Beta = -2.11, 95% CI: -2.98 to -1.23,  $p = 2.47 \times 10^{-6}$ ),  
248 cML-MA-BIC (Beta = -2.17, 95% CI: -3.49 to -0.86,  $p = 1.19 \times 10^{-3}$ ), Weighted  
249 median (Beta = -2.43, 95% CI: -4.05 to -0.81,  $p = 3.29 \times 10^{-3}$ ), and other methods. In  
250 addition, the IVW estimate indicated a protective effect of the *Akkermansia* genus on  
251 high-grade irAEs (Beta = 1.27, 95% CI: 0.28 to 2.25,  $p = 0.01$ ), and this finding was  
252 confirmed by the IVW estimate of its paternal taxon *Verrucomicrobiaceae* (Beta =  
253 1.27, 95% CI: 0.29 to 2.25,  $p = 0.01$ ). The IVW estimate of *Anaerostipes* genus also  
254 indicated a suggestive protective effect against high-grade irAEs (Beta = 2.1, 95% CI:  
255 0.85 to 3.35,  $p = 1.02 \times 10^{-3}$ ), as well as cML-MA-BIC (Beta = 2.17, 95% CI: 0.57 to

256 3.77,  $p = 7.88 \times 10^{-3}$ ). Moreover, significant effects of the *Coprococcus3* (Beta =  
257 -2.04, 95% CI: -2.7 to -1.39,  $p = 8.93 \times 10^{-10}$ ), *Collinsella* (Beta = -1.12, 95% CI: -1.7  
258 to -0.53,  $p = 1.7 \times 10^{-4}$ ), and *Eubacterium (fissicatena group)* genus (Beta = -0.73, 95%  
259 CI: -1.01 to -0.46,  $p = 1.93 \times 10^{-7}$ ) were all revealed by IVW estimate, indicating an  
260 increased risk of high-grade irAEs. Scatter plots reflecting the effect size of IVs on  
261 both bacterial taxa and high-grade irAEs are shown in **Figure 4**.

262 In the subsequent analysis of heterogeneity and horizontal pleiotropy, Cochran's  
263 Q statistics revealed no significant heterogeneity ( $p$ -value > 0.05) among the IVs for  
264 the gut bacterial taxa in high-grade irAEs analysis (see **Table 1**). No significant  
265 evidence for directional horizontal pleiotropy was found in the MR-Egger regression  
266 intercept analysis and MR PRESSO global test (**Table 1 and Table S4**). Additionally,  
267 the LOO analysis identified no predominant SNP that influenced the results (**Figure**  
268 **6**). We further performed reverse MR analysis and demonstrated no reverse causation  
269 exists between high-grade irAEs and the abundance of gut bacterial taxa (**Table S6**).

270

### 271 **3.3 Main MR results and sensitivity analysis for all-grade irAEs**

272 **Figure 3** presents the association between bacterial taxa and all-grade irAEs. It is  
273 noteworthy that the deleterious impact of the *Lachnospiraceae* family was also  
274 detected in all-grade irAEs, as revealed by IVW (Beta = -2.05, 95% CI: -3.27 to -0.82,  
275  $p = 1.06 \times 10^{-3}$ ), cML-MA-BIC (Beta = -2.21, 95% CI: -3.32 to -1.1,  $p = 9.16 \times 10^{-5}$ ),  
276 and Weighted median estimates (Beta = -1.72, 95% CI: -3.2 to -0.24,  $p = 2.25 \times 10^{-2}$ ).  
277 The IVW estimate of *Roseburia* genus also showed an increased risk of all-grade  
278 irAEs (Beta = -2.07, 95% CI: -3.21 to -0.93,  $p = 3.76 \times 10^{-4}$ ). Consistent results were  
279 observed in ML (Beta = -2.07, 95% CI: -3.67 to -0.47,  $p = 1.14 \times 10^{-2}$ ) and  
280 cML-MA-BIC (Beta = -2.08, 95% CI: -3.71 to -0.45,  $p = 1.23 \times 10^{-2}$ ) estimates. On  
281 the contrary, *RuminococcaceaeUCG004* (Beta = 1.07, 95% CI: 0.43 to 1.72,  $p = 1.05$   
282  $\times 10^{-3}$ ) and *DefluviitaleaceaeUCG011* (Beta = 0.82, 95% CI: 0.38 to 1.25,  $p = 2.15 \times$   
283  $10^{-4}$ ) were identified to decrease the risk of all-grade irAEs according to the IVW  
284 approach. Subsequently, the results for *RuminococcaceaeUCG004* were consistent  
285 with the cML-MA-BIC (Beta = 1.1, 95% CI: 0.04 to 2.15,  $p = 4.12 \times 10^{-2}$ ) and ML  
286 method (Beta = 1.09, 95% CI: 0.04 to 2.14,  $p = 4.16 \times 10^{-2}$ ). Moreover, the IVW  
287 estimates suggested that *Porphyromonadaceae* (Beta = -1.11, 95% CI: -1.83 to -0.39,  
288  $p = 2.46 \times 10^{-3}$ ), *Eubacterium (brachy group)* (Beta = -0.71, 95% CI: -1.14 to -0.27,  $p$   
289  $= 1.38 \times 10^{-3}$ ), and *Peptococcus* (Beta = -0.71, 95% CI: -1.24 to -0.18,  $p = 8.82 \times 10^{-3}$ )  
290 may increase the risk of all-grade irAEs. Scatter plots reflecting the effect size of each  
291 IV on both bacterial taxa and all-grade irAEs are shown in **Figure 5**.

292 Similarly, Cochran's Q statistics indicated an absence of notable heterogeneity in  
293 the IVs of gut bacterial taxa (refer to **Table 1**). In addition, the results from the  
294 MR-Egger regression intercept analysis and the MR PRESSO global test



295 demonstrated no significant evidence of directional horizontal pleiotropy (**Table 1**  
296 **and Table S4**). Next, no significant single SNP was identified in the LOO analysis  
297 that influenced the results (**Figure 7**). Overall, these results provide evidence for the  
298 association between specific gut bacterial taxa and the development of high-grade and  
299 all-grade irAEs, and highlight the potential role of the gut microbiota in irAEs.

300

#### 301 **4. Discussion**

302 In this study, we implemented the summary statistics of gut microbiota from the  
303 largest GWAS meta-analysis and the summary statistics of irAEs in the MR analysis.  
304 Fourteen gut bacterial taxa were identified to be causally associated with high-grade  
305 and all-grade irAEs. Among those bacterial taxa, *Lachnospiraceae* showed a strong  
306 causal association with an increased risk of both irAEs phenotypes. Additionally, we  
307 found robust evidence indicating that *Ruminiclostridium6* predisposes ICIs receivers  
308 to the development of high-grade irAEs. *Coprococcus3*, *Collinsella*, and *Eubacterium*  
309 (*fissicatena* group) were also associated with an increased risk of high-grade irAEs,  
310 while *Akkermansia*, *Verrucomicrobiaceae*, and *Anaerostipes* exhibited protective roles  
311 in high-grade irAEs. For all-grade irAEs, *Porphyromonadaceae*, *Roseburia*,  
312 *Eubacterium* (*brachy* group), and *Peptococcus* were associated with an elevated risk,  
313 while *RuminococcaceaeUCG004* and *DefluviitaleaceaeUCG011* were associated with  
314 a reduced risk.

315 Several observational studies have demonstrated associations between gut  
316 microbiota and irAEs (11,17–19,39,40). *Lachnospiraceae* species (such as  
317 *Coprococcus* and *Roseburia*), which are obligately anaerobic, variably spore-forming  
318 bacteria, were found to correlate with increased risk of various types of irAEs  
319 (17,18,41). In a more recent study, two species of the *Lachnospiraceae* family were  
320 specifically enriched in irAEs that occur in endocrine organs (42). Consistent with  
321 these findings, we identified the *Lachnospiraceae* family, and its two genera (i.e.,  
322 *Coprococcus3* and *Roseburia*) associated with an increased risk of irAEs. Importantly,  
323 the detrimental influence of the *Lachnospiraceae* family was observed in high-grade  
324 irAEs and all-grade irAEs, providing further validity and robustness to our study.  
325 *Ruminiclostridium6* has been less studied in irAEs, but some studies have observed its  
326 accumulation in a mouse model of DSS-induced colitis. While treated with phloretin  
327 (a dihydrochalcone flavonoid) or sodium butyrate (one of the short chain fatty acids  
328 [SCFAs]), both of which alleviates DSS-induced colitis, the abundance of  
329 *Ruminiclostridium6* was reduced (43,44). In addition, the *Ruminiclostridium* genus  
330 has also been associated with autoimmune-related diseases, such as experimental  
331 multiple sclerosis model and Alzheimer's disease (45,46). Based on our strong  
332 association of *Ruminiclostridium6* with increased risk of high-grade irAEs, it is

333 suggested that *Ruminiclostridium6* may play a pivotal role in the development of  
334 autoimmune conditions and could be a potential target for relieving irAEs symptoms,  
335 although more evidence is needed.

336 *Akkermansia muciniphila*, an anaerobic gram-negative species that belongs to  
337 *Akkermansia* genus, and *Verrucomicrobiaceae* family, has gained much attention in  
338 immunotherapy due to their association with a favorable response in ICIs therapy  
339 (47–49). *Akkermansia muciniphila* has also been shown to exhibit a protective role in  
340 ICIs-associated colitis (50). Mechanically, Wang et al. demonstrated that *Akkermansia*  
341 *muciniphila* and its purified membrane protein mitigated colitis by regulating  
342 macrophages and CD8+ T cells in the colon tissue (51). Our study further supported  
343 the protective role of *Akkermansia* in high-grade irAEs. *Ruminococcaceae*, a key  
344 family of bacteria producing short-chain fatty acids (SCFAs), has been observed to be  
345 enriched in ICIs responders without severe irAEs (11). Previous studies have found  
346 that *Faecalibacterium prausnitzii*, a species belonging to the *Ruminococcaceae* family,  
347 was decreased in non-responders and those experiencing severe irAEs (11,17,41).  
348 These findings suggest a potential role of *Ruminococcaceae* as protective bacteria,  
349 possibly through the facilitation of SCFAs accumulation, in the mitigation of irAEs.  
350 *Collinsella* and *Anaerostipes* have limited evidence in irAEs, but the *Collinsella*  
351 genus has been reported to increase the production of IL-17A and enhance rheumatoid  
352 arthritis severity (52). In contrast, *Anaerostipes*, which belongs to the  
353 *Lachnospiraceae* family, was conversely associated with the risk of high-grade irAEs  
354 in our study (11,18). These discrepancies observed in previous clinical studies might  
355 be attributed to several factors, including limited sample sizes in previous  
356 observational studies, heterogeneity among the samples, and inadequate exploration  
357 of the taxonomic classification at the genus level of the gut microbiota. Therefore, a  
358 more detailed taxonomy for gut microbiota is crucial in dissecting the underlying  
359 mechanisms.

360 Gut microbiota plays a pivotal role in modulating human immune homeostasis,  
361 and an imbalance in gut microbial composition, known as gut dysbiosis, has been  
362 implicated in several autoimmune diseases (15,16,53). Notably, irAEs resemble  
363 autoimmune diseases in many aspects (37,54,55). Thus, despite the underlying  
364 mechanisms by which gut microbiota manipulates the development of irAEs remain  
365 poorly understood, we hypothesize that there might be some shared etiology of  
366 microbiota in autoimmune diseases and irAEs. These mechanisms include: (1)  
367 “Molecular mimicry”: Evidence has shown that exposure to homologous amino acid  
368 sequences or epitopes of microbiota and aberrant activation of autoreactive B or T  
369 cells leads to multiple autoimmune diseases, such as multiple sclerosis (56),  
370 Guillain–Barré syndrome (57), Type 1 diabetes (58), Rheumatoid arthritis (59), and  
371 primary biliary cholangitis (60), which is referred to as “molecular mimicry” (61). It

372 is believed that the systematic activation of the immune system during ICIs treatment  
373 triggers irAEs by bypassing self-tolerance in normal organs. One intriguing fact is  
374 that most irAEs occur in barrier organs (e.g., the intestinal tract, skin, and lungs)  
375 (54,62). This implies that the activated immune response might target the commensal  
376 microbiome as antigenic targets, although this hypothesis has not been fully  
377 demonstrated. (2) Decreased accumulation of SCFAs: SCFAs, including acetate,  
378 propionate, and butyrate, are a group of organic compounds primarily produced by the  
379 gut microbiota during the fermentation of dietary fibers. These metabolites were  
380 shown to improve the anti-cancer function of effector T cells, but they also seem to  
381 exhibit anti-inflammatory characteristics (63,64). Butyrate, one of the well-studied  
382 SCFAs, was shown to inhibit the activation of NF- $\kappa$ B and its downstream pathway  
383 (65), thereby reducing the production of pro-inflammatory cytokines such as IL-8 (66),  
384 while increasing the levels of anti-inflammatory factors like IL-10 (67). Moreover,  
385 SCFAs serve as a key energy source for colonocytes and maintain intestinal barrier  
386 integrity (68). Thus, the reduced abundance of SCFAs-producing bacteria along with  
387 its metabolites may participate in the development of irAEs. (3) Other mechanisms:  
388 Stimulation of the immune response by microbial-associated molecular patterns (e.g.,  
389 include lipopolysaccharides (LPS), lipoproteins, flagellin and bacterial DNA) (69)  
390 and compromised vitamin B and polyamine metabolism that associated with gut  
391 dysbiosis (19) may also contribute to irAEs.

392 Taken together, the gut microbiota and the human immune system maintain a  
393 delicate balance under normal physiological conditions. Once the balance has been  
394 disturbed (e.g., ICIs treatment), the dysregulated microbiota might lead to the  
395 development of undesirable irAEs. The primary management strategy for irAEs (>  
396 grade 2) involves the suspension of ICIs and/or utilizing immunosuppressive therapy  
397 (70). Nevertheless, one concern is that discontinuing ICIs or using  
398 immunosuppressants may compromise treatment efficacy. Ideally, approaches to  
399 boost ICIs efficacy while reducing the accompanied irAEs are to be expected in the  
400 future. FMT, an approach to modulate gut microbiota, has been shown to increase  
401 ICIs efficacy in melanoma patients (71,72), and emerging evidence has demonstrated  
402 the mitigation of ICIs-related colitis through FMT in clinical practice (73).  
403 Interestingly, while irAEs and ICIs efficacy are often considered two sides of the  
404 same coin, certain gut bacteria, such as *Akkermansia muciniphila* and  
405 *Faecalibacterium prausnitzii*, have been shown to ameliorate irAEs and reinforce  
406 ICIs efficacy at the same time (74). This suggests that targeting gut microbiota could  
407 be an ideal approach to relieve irAEs symptoms and maintain ICIs efficacy, but  
408 further real-world evidence is needed to support this hypothesis.

409 Our study possesses several strengths. Firstly, we applied the MR approach to the  
410 causal-association analysis between gut microbiota and irAEs, which effectively

411 mitigates the influence of confounding factors and provides robust causal inference.  
412 Secondly, we conducted reverse MR analyses, confirming the absence of reverse  
413 causation, thereby enhancing the validity of our study. Thirdly, the genetic variants  
414 associated with the gut microbiota were obtained from a comprehensive meta-analysis  
415 of GWAS, ensuring the reliability of the instrumental variables used in the MR  
416 analysis. Moreover, we incorporated several pleiotropy-robust methods such as MR  
417 PRESSO and cML-MA-BIC, further strengthening the robustness of our study.  
418 However, there are also certain inherent limitations in our study that should be  
419 considered when interpreting the findings. Firstly, our analysis is based on  
420 European-derived GWAS summary statistics, which might confine the generalization  
421 of the findings to other populations. Secondly, due to the utilization of summary  
422 statistics instead of raw data in the analysis, subgroup analyses based on ICIs regimes  
423 (e.g. PD-1/PD-L1 group, CTLA-4 group, and combined therapy group) could not be  
424 performed. Thirdly, the gut microbiota is shaped by multiple environmental factors,  
425 which confines the number of the identified significant gene loci in the GWAS (26).  
426 Thus, we relaxed the significant threshold of IVs to  $1 \times 10^{-5}$  (29) and employed  
427 Bonferroni correction to mitigate potential false positive results.

428

## 429 **5. Conclusion**

430 In summary, our findings suggest that *Lachnospiraceae* and *Akkermansia* et al.  
431 were causally associated with the development of irAEs. However, whether the FMT  
432 or probiotics could be used as interventional approaches to mitigate irAEs while  
433 reserving ICIs efficacy, additional randomized clinical trials (RCTs) are warranted.  
434 Furthermore, in-depth investigations are needed to elucidate the precise mechanisms  
435 through which the gut microbiota influences the development of irAEs.

436

## 437 **Declarations**

### 438 **Acknowledgment:**

439 We acknowledge all the investigators who have made their GWAS data available.

440

### 441 **Author contributions**

442 B. L. conceptualized this study. B. L. and T. J., Z. L. were involved in the analyses  
443 and manuscript drafting of this study. X. G. and X. Z. were involved in the data  
444 curation. B. L., T. J. X. Y., Z. C., and L. D. were involved in the interpretation of the  
445 methodology and results. B. L. and Z. L. were involved in the visualization of the  
446 results. B. Z. was involved in obtaining funding and critical revision of the  
447 manuscript.

448

449 **Funding:**

450 This study was supported by the National Nature Science Foundations of China  
451 (Grant number 82203108), China Postdoctoral Science Foundation (Grant number  
452 2022M722275), and the Key R&D Program of Sichuan Province, China (Grant  
453 number 2023YFS0278).

454

455 **Conflict of Interest:**

456 All authors declare no conflict of interest.

457

458 **Data Availability:**

459 This study was conducted using public-available data. The GWAS summary statistics  
460 for gut microbiota are available at [www.mibiogen.org](http://www.mibiogen.org), and GWAS summary statistics  
461 for irAEs are available at <https://zenodo.org/record/6800429>.

462

463

464 **Supplementary Information**

465 **Table S1.** All Instrumental variables used for gut microbiota in the MR analysis.

466 **Table S2.** Full results of primary MR analysis between bacterial taxa and all-grade  
467 irAEs.

468 **Table S3.** Full results of primary MR analysis between bacterial taxa and high-grade  
469 irAEs.

470 **Table S4.** Results of MR PRESS Global test.

471 **Table S5.** Instrumental variables for irAEs in the reverse MR analysis.

472 **Table S6.** Results of reverse MR analysis between all-grade irAEs and the identified  
473 significant gut bacterial taxa.

474 **Table S7.** Results of reverse MR analysis between high-grade irAEs and the identified  
475 significant gut bacterial taxa.

476 **Table S8.** Results of heterogeneity and horizontal pleiotropy analysis in reverse MR  
477 analysis.

478 **Table S9.** PhenoScanner results of instrumental variables used for significant bacterial  
479 taxa in the MR analysis.

480

481

**Table 1. Results of heterogeneity and horizontal pleiotropy analysis.**

bacterial taxa (exposure)	irAEs (outcome)	Heterogeneity test			Horizontal pleiotropy results		
		Cochran's Q	df	p-value	Egger intercept	SE	p-value
<i>Lachnospiraceae</i>	High-grade irAEs	5.18	12	0.95	0.04	0.11	0.73
<i>Verrucomicrobiaceae</i>	High-grade irAEs	4.18	7	0.76	0.36	0.61	0.57
<i>Eubacterium (fissicatena group)</i>	High-grade irAEs	0.33	4	0.99	0.07	0.53	0.9
<i>Akkermansia</i>	High-grade irAEs	4.18	7	0.76	0.37	0.61	0.56
<i>Anaerostipes</i>	High-grade irAEs	4.13	6	0.66	0.38	0.2	0.11
<i>Collinsella</i>	High-grade irAEs	0.82	6	0.99	-0.19	0.23	0.43
<i>Coprococcus3</i>	High-grade irAEs	0.47	4	0.98	-0.28	0.46	0.59
<i>Ruminiclostridium6</i>	High-grade irAEs	3.54	7	0.83	-0.17	0.18	0.38
<i>Lachnospiraceae</i>	All-grade irAEs	17.3	12	0.14	0.09	0.11	0.43
<i>Porphyromonadaceae</i>	All-grade irAEs	0.66	4	0.96	0.05	0.28	0.87
<i>Eubacterium (brachy group)</i>	All-grade irAEs	1.41	5	0.92	-0.11	0.29	0.73
<i>DefluviitaleaceaeUCG011</i>	All-grade irAEs	0.48	4	0.98	-0.03	0.25	0.92
<i>Peptococcus</i>	All-grade irAEs	1.87	5	0.87	-0.12	0.24	0.66
<i>Roseburia</i>	All-grade irAEs	3.75	7	0.81	-0.31	0.22	0.21
<i>RuminococcaceaeUCG004</i>	All-grade irAEs	2.73	7	0.91	-0.23	0.3	0.47

df, degree of freedom; SE, standard error.

482

483

484

485 **References:**

- 486 1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade.  
487 Science. 2018 Mar 23;359(6382):1350–5.
- 488 2. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.  
489 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J  
490 Med. 2010 Aug 19;363(8):711–23.
- 491 3. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al.  
492 Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med.  
493 2015 Nov 5;373(19):1803–13.
- 494 4. Mj O, R M, Ji L, S L, Hj L, Ma M, et al. Nivolumab in patients with metastatic  
495 DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer  
496 (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol [Internet].  
497 2017 Sep [cited 2023 Feb 17];18(9). Available from:  
498 <https://pubmed.ncbi.nlm.nih.gov/28734759/>
- 499 5. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et  
500 al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N  
501 Engl J Med. 2018 May 31;378(22):2078–92.
- 502 6. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat  
503 Commun. 2020 Jul 30;11(1):3801.
- 504 7. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et  
505 al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J  
506 Med. 2015 May 21;372(21):2006–17.
- 507 8. Suresh K, Naidoo J. Lower Survival in Patients Who Develop Pneumonitis  
508 Following Immunotherapy for Lung Cancer. Clin Lung Cancer. 2020 May  
509 1;21(3):e169–70.
- 510 9. Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R,  
511 Rutkowski P, et al. Efficacy and Safety Outcomes in Patients With Advanced  
512 Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because  
513 of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin  
514 Oncol Off J Am Soc Clin Oncol. 2017 Dec 1;35(34):3807–14.
- 515 10. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et  
516 al. Management of Immune-Related Adverse Events in Patients Treated With  
517 Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology  
518 Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018 Jun  
519 10;36(17):1714–68.
- 520 11. Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, et al.  
521 Diet-driven microbial ecology underpins associations between cancer immunotherapy  
522 outcomes and the gut microbiome. Nat Med. 2022 Nov;28(11):2344–52.
- 523 12. Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y, et al. Association of antibiotic  
524 treatment with immune-related adverse events in patients with cancer receiving  
525 immunotherapy. J Immunother Cancer. 2022 Jan;10(1):e003779.
- 526 13. Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, et al.

- 527 Impact of antibiotic therapy on the development and response to treatment of immune  
528 checkpoint inhibitor-mediated diarrhea and colitis. *J Immunother Cancer*. 2019 Sep  
529 5;7(1):242.
- 530 14. Mohiuddin JJ, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, et al.  
531 Association of Antibiotic Exposure With Survival and Toxicity in Patients With  
532 Melanoma Receiving Immunotherapy. *J Natl Cancer Inst*. 2021 Feb 1;113(2):162–70.
- 533 15. Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut Microbiota and  
534 Immune System Interactions. *Microorganisms*. 2020 Oct 15;8(10):1587.
- 535 16. Belkaid Y, Hand T. Role of the Microbiota in Immunity and inflammation. *Cell*.  
536 2014 Mar 27;157(1):121–41.
- 537 17. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al.  
538 Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma  
539 patients treated with ipilimumab. *Ann Oncol Off J Eur Soc Med Oncol*. 2017 Jun  
540 1;28(6):1368–79.
- 541 18. McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, et al.  
542 Intestinal microbiota signatures of clinical response and immune-related adverse  
543 events in melanoma patients treated with anti-PD-1. *Nat Med*. 2022  
544 Mar;28(3):545–56.
- 545 19. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal  
546 microbiome analyses identify melanoma patients at risk for  
547 checkpoint-blockade-induced colitis. *Nat Commun*. 2016 Feb 2;7:10391.
- 548 20. Bajinka O, Tan Y, Abdelhalim KA, Özdemir G, Qiu X. Extrinsic factors  
549 influencing gut microbes, the immediate consequences and restoring eubiosis. *AMB*  
550 *Express*. 2020 Jul 25;10(1):130.
- 551 21. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. *Lancet*  
552 *Lond Engl*. 1986 Mar 1;1(8479):507–8.
- 553 22. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation  
554 studies: a guide, glossary, and checklist for clinicians. *BMJ*. 2018 Jul 12;362:k601.
- 555 23. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal  
556 inference in epidemiological studies. *Hum Mol Genet*. 2014 Sep 15;23(R1):R89–98.
- 557 24. Chen L, Peters JE, Prins B, Persyn E, Traylor M, Surendran P, et al. Systematic  
558 Mendelian randomization using the human plasma proteome to discover potential  
559 therapeutic targets for stroke. *Nat Commun*. 2022 Oct 17;13:6143.
- 560 25. Zhang X, Theodoratou E, Li X, Farrington SM, Law PJ, Broderick P, et al.  
561 Genetically predicted physical activity levels are associated with lower colorectal  
562 cancer risk: a Mendelian randomisation study. *Br J Cancer*. 2021 Mar;124(7):1330–8.
- 563 26. Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J,  
564 Demirkan A, et al. Large-scale association analyses identify host factors influencing  
565 human gut microbiome composition. *Nat Genet*. 2021 Feb;53(2):156–65.
- 566 27. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, et al.  
567 Germline variants associated with toxicity to immune checkpoint blockade. *Nat Med*.  
568 2022 Dec;28(12):2584–91.
- 569 28. Liu X, Tong X, Zou Y, Lin X, Zhao H, Tian L, et al. Mendelian randomization  
570 analyses support causal relationships between blood metabolites and the gut



- 571 microbiome. *Nat Genet.* 2022 Jan;54(1):52–61.
- 572 29. Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Vösa U, et al.
- 573 Causal relationships among the gut microbiome, short-chain fatty acids and metabolic
- 574 diseases. *Nat Genet.* 2019 Apr;51(4):600–5.
- 575 30. Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent
- 576 Developments in Mendelian Randomization Studies. *Curr Epidemiol Rep.*
- 577 2017;4(4):330–45.
- 578 31. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al.
- 579 Guidelines for performing Mendelian randomization investigations. *Wellcome Open*
- 580 *Res.* 2019;4:186.
- 581 32. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal
- 582 pleiotropy in causal relationships inferred from Mendelian randomization between
- 583 complex traits and diseases. *Nat Genet.* 2018 May;50(5):693–8.
- 584 33. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple
- 585 instrumental variables in Mendelian randomization: comparison of allele score and
- 586 summarized data methods. *Stat Med.* 2016 May 20;35(11):1880–906.
- 587 34. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
- 588 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
- 589 Estimator. *Genet Epidemiol.* 2016 May;40(4):304–14.
- 590 35. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data
- 591 Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol.*
- 592 2017 Dec 1;46(6):1985–98.
- 593 36. Xue H, Shen X, Pan W. Constrained maximum likelihood-based Mendelian
- 594 randomization robust to both correlated and uncorrelated pleiotropic effects. *Am J*
- 595 *Hum Genet.* 2021 Jul 1;108(7):1251–69.
- 596 37. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al.
- 597 Management of immune checkpoint blockade dysimmune toxicities: a collaborative
- 598 position paper. *Ann Oncol Off J Eur Soc Med Oncol.* 2016 Apr;27(4):559–74.
- 599 38. Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, et al. Risk of
- 600 irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors
- 601 for stage III or IV melanoma: results from a matched case–control study. *Ann Rheum*
- 602 *Dis.* 2022 Oct 1;81(10):1445–52.
- 603 39. Liu T, Xiong Q, Li L, Hu Y. Intestinal microbiota predicts lung cancer patients at
- 604 risk of immune-related diarrhea. *Immunotherapy.* 2019 Apr;11(5):385–96.
- 605 40. Chau J, Yadav M, Liu B, Furqan M, Dai Q, Shahi S, et al. Prospective correlation
- 606 between the patient microbiome with response to and development of
- 607 immune-mediated adverse effects to immunotherapy in lung cancer. *BMC Cancer.*
- 608 2021 Jul 13;21(1):808.
- 609 41. Liu W, Ma F, Sun B, Liu Y, Tang H, Luo J, et al. Intestinal Microbiome
- 610 Associated With Immune-Related Adverse Events for Patients Treated With
- 611 Anti-PD-1 Inhibitors, a Real-World Study. *Front Immunol.* 2021 Dec 16;12:756872.
- 612 42. Zhang Y, Cheng S, Zou H, Han Z, Xie T, Zhang B, et al. Correlation of the gut
- 613 microbiome and immune-related adverse events in gastrointestinal cancer patients
- 614 treated with immune checkpoint inhibitors. *Front Cell Infect Microbiol [Internet].*

- 615 2023 [cited 2023 Jun 18];13. Available from:  
616 <https://www.frontiersin.org/articles/10.3389/fcimb.2023.1099063>  
617 43. Dou X, Gao N, Yan D, Shan A. Sodium Butyrate Alleviates Mouse Colitis by  
618 Regulating Gut Microbiota Dysbiosis. *Anim Open Access J MDPI*. 2020 Jul  
619 7;10(7):1154.  
620 44. Wu M, Li P, An Y, Ren J, Yan D, Cui J, et al. Phloretin ameliorates dextran  
621 sulfate sodium-induced ulcerative colitis in mice by regulating the gut microbiota.  
622 *Pharmacol Res*. 2019 Dec;150:104489.  
623 45. Johanson DM, Goertz JE, Marin IA, Costello J, Overall CC, Gaultier A.  
624 Experimental autoimmune encephalomyelitis is associated with changes of the  
625 microbiota composition in the gastrointestinal tract. *Sci Rep*. 2020 Sep  
626 16;10(1):15183.  
627 46. Ning J, Huang SY, Chen SD, Zhang YR, Huang YY, Yu JT. Investigating Casual  
628 Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases:  
629 A Mendelian Randomization Study. *J Alzheimers Dis JAD*. 2022;87(1):211–22.  
630 47. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut  
631 microbiome influences efficacy of PD-1–based immunotherapy against epithelial  
632 tumors. *Science*. 2018 Jan 5;359(6371):91–7.  
633 48. Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, et al.  
634 Cross-cohort gut microbiome associations with immune checkpoint inhibitor response  
635 in advanced melanoma. *Nat Med*. 2022 Mar;28(3):535–44.  
636 49. Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal  
637 *Akkermansia muciniphila* predicts clinical response to PD-1 blockade in patients with  
638 advanced non-small-cell lung cancer. *Nat Med*. 2022 Feb;28(2):315–24.  
639 50. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL,  
640 et al. Fecal microbiota transplantation for refractory immune checkpoint  
641 inhibitor-associated colitis. *Nat Med*. 2018 Dec;24(12):1804–8.  
642 51. Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, et al. A purified membrane  
643 protein from *Akkermansia muciniphila* or the pasteurised bacterium blunts colitis  
644 associated tumourigenesis by modulation of CD8+ T cells in mice. *Gut*. 2020  
645 Nov;69(11):1988–97.  
646 52. Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, et al. An  
647 expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis.  
648 *Genome Med*. 2016 Apr 21;8(1):43.  
649 53. Miyauchi E, Shimokawa C, Steimle A, Desai MS, Ohno H. The impact of the gut  
650 microbiome on extra-intestinal autoimmune diseases. *Nat Rev Immunol*. 2023  
651 Jan;23(1):9–23.  
652 54. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse  
653 effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.  
654 *Nat Rev Clin Oncol*. 2019 Sep;16(9):563–80.  
655 55. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events  
656 Associated with Immune Checkpoint Blockade. *N Engl J Med*. 2018 Jan  
657 11;378(2):158–68.  
658 56. Du C, Yao SY, Ljunggren-Rose Å, Sriram S. *Chlamydia pneumoniae* Infection of

- 659 the Central Nervous System Worsens Experimental Allergic Encephalitis. *J Exp Med*.  
660 2002 Dec 16;196(12):1639–44.
- 661 57. Rodríguez Y, Rojas M, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C,  
662 Monsalve DM, et al. Guillain–Barré syndrome, transverse myelitis and infectious  
663 diseases. *Cell Mol Immunol*. 2018 Jun;15(6):547–62.
- 664 58. Gülden E, Wong FS, Wen L. The gut microbiota and Type 1 Diabetes. *Clin*  
665 *Immunol*. 2015 Aug 1;159(2):143–53.
- 666 59. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al.  
667 Antibodies to citrullinated  $\alpha$ -enolase peptide 1 are specific for rheumatoid arthritis  
668 and cross-react with bacterial enolase. *Arthritis Rheum*. 2008;58(10):3009–19.
- 669 60. Tanaka A, Leung PSC, Gershwin ME. Pathogen infections and primary biliary  
670 cholangitis. *Clin Exp Immunol*. 2019 Jan 1;195(1):25–34.
- 671 61. Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y,  
672 Ramírez-Santana C, et al. Molecular mimicry and autoimmunity. *J Autoimmun*. 2018  
673 Dec;95:100–23.
- 674 62. Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from  
675 checkpoint inhibitors. *Trends Cancer*. 2023 Jul 1;9(7):543–53.
- 676 63. Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain  
677 fatty acids induce both effector and regulatory T cells by suppression of histone  
678 deacetylases and regulation of the mTOR–S6K pathway. *Mucosal Immunol*. 2015  
679 Jan;8(1):80–93.
- 680 64. Luu M, Riester Z, Baldrich A, Reichardt N, Yuille S, Buseti A, et al. Microbial  
681 short-chain fatty acids modulate CD8+ T cell responses and improve adoptive  
682 immunotherapy for cancer. *Nat Commun*. 2021 Jul 1;12(1):4077.
- 683 65. Zhou G, Zhang N, Meng K, Pan F. Interaction between gut microbiota and  
684 immune checkpoint inhibitor-related colitis. *Front Immunol*. 2022 Oct  
685 27;13:1001623.
- 686 66. BÖCKER U, NEBE T, HERWECK F, HOLT L, PANJA A, JOBIN C, et al.  
687 Butyrate modulates intestinal epithelial cell-mediated neutrophil migration. *Clin Exp*  
688 *Immunol*. 2003 Jan;131(1):53–60.
- 689 67. Lee C, Kim BG, Kim JH, Chun J, Im JP, Kim JS. Sodium butyrate inhibits the  
690 NF- $\kappa$ B signaling pathway and histone deacetylation, and attenuates experimental  
691 colitis in an IL-10 independent manner. *Int Immunopharmacol*. 2017 Oct;51:47–56.
- 692 68. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM.  
693 The role of short-chain fatty acids in the interplay between diet, gut microbiota, and  
694 host energy metabolism. *J Lipid Res*. 2013 Sep;54(9):2325–40.
- 695 69. Wang Y, Jenq RR, Wargo JA, Watowich SS. Microbiome influencers of  
696 checkpoint blockade-associated toxicity. *J Exp Med*. 2023 Mar 6;220(3):e20220948.
- 697 70. Schneider BJ, Naidoo J, Santomaso BD, Lacchetti C, Adkins S, Anadkat M, et al.  
698 Management of Immune-Related Adverse Events in Patients Treated With Immune  
699 Checkpoint Inhibitor Therapy: ASCO Guideline Update. *J Clin Oncol*. 2021 Dec  
700 20;39(36):4073–126.
- 701 71. Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison  
702 RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in

703 melanoma patients. *Science*. 2021 Feb 5;371(6529):595–602.  
704 72. Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al.  
705 Fecal microbiota transplant promotes response in immunotherapy-refractory  
706 melanoma patients. *Science*. 2021 Feb 5;371(6529):602–9.  
707 73. Chen M, Liu M, Li C, Peng S, Li Y, Xu X, et al. Fecal Microbiota  
708 Transplantation Effectively Cures a Patient With Severe Bleeding Immune  
709 Checkpoint Inhibitor-Associated Colitis and a Short Review. *Front Oncol*. 2022 Jun  
710 10;12:913217.  
711 74. Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al.  
712 Enterocolitis due to immune checkpoint inhibitors: a systematic review. *Gut*. 2018  
713 Nov 1;67(11):2056–67.

714

### 715 **Figure legends:**

716 **Figure 1.** Overview of the study design.

717 Initially, IVs were selected from the summary GWAS data pertaining to the gut  
718 microbiota and irAEs. Subsequently, by employing thresholds of p-value (IVW) <  
719 0.05 and p-value (MR PRESSO) < 0.05, the identified gut microbiota that exhibited  
720 statistically significant associations were taken into further analysis (Created with  
721 BioRender.com).

722 **Figure 2.** Forest plots of MR results for the causal association between the identified  
723 eight gut microbial taxa and high-grade irAEs. NSNP = number of SNPs; Beta =  
724 effect size from the exposure to the outcome; CI = confidence interval.

725 **Figure 3.** Forest plots of MR results for the causal association between the identified  
726 seven gut microbial taxa and all-grade irAEs. NSNP = number of SNPs; Beta = effect  
727 size from the exposure to the outcome; CI = confidence interval.

728 **Figure 4.** Scatter plots of MR analysis between the gut microbial taxa and high-grade  
729 irAEs.

730 **Figure 5.** Scatter plots of MR analysis between the gut microbial taxa and all-grade  
731 irAEs.


732 **Figure 6.** Leave-one-out plots of MR analysis between the gut microbial taxa and  
733 high-grade irAEs.

734 **Figure 7.** Leave-one-out plots of MR analysis between the gut microbial taxa and  
735 all-grade irAEs.

736

737 **Figure S1.** Illustration of MR assumptions


738




# High-grade irAEs

## Family level

### *Lachnospiraceae*




### *Verrucomicrobiaceae*




## Genus level


### *Ruminiclostridium6*




### *Coprococcus3*




### *Anaerostipes*




### *Akkermansia*



### *Collinsella*




### *Eubacterium (fissicatena group)*




# All-grade irAEs

## Family level

### *Lachnospiraceae*




### *Porphyromonadaceae*




## Genus level


### *Roseburia*




### *Ruminococcaceae* UCG004




### *Defluviitaleaceae* UCG011



### *Eubacterium* (brachy group)






### *Peptococcus*






# High-grade irAEs




## Family level



## Genus level



medRxiv preprint doi: <https://doi.org/10.1101/2023.07.24.23292742>; this version posted July 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).








# All-grade irAEs

## Family level

### *Lachnospiraceae*




### *Porphyromonadaceae*




## Genus level


### *Roseburia*




### *Ruminococcaceae*UCG004




### *Defluviitaleaceae*UCG011



### *Eubacterium* (brachy group)




### *Peptococcus*




# High-grade irAEs

## Family level

### *Lachnospiraceae*




### *Verrucomicrobiaceae*




## Genus level


### *Ruminiclostridium6*




### *Coprococcus3*




### *Anaerostipes*




### *Akkermansia*



### *Collinsella*



### *Eubacterium (fissicatena group)*




bioRxiv preprint doi: <https://doi.org/10.1101/2023.07.27.552100>; this version posted July 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.


# All-grade irAEs

## Family level

### *Lachnospiraceae*




### *Porphyromonadaceae*




## Genus level


### *Roseburia*




### *Ruminococcaceae* UCG004




### *Defluviitaleaceae* UCG011



### *Eubacterium* (brachy group)



### *Peptococcus*



bioRxiv preprint doi: <https://doi.org/10.1101/2023.07.27.555100>; this version posted July 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.